Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone

Oncology

Volumn 76, Issue 3, 2009, Pages 209-211

  Christodoulou, C ^a,b,c   Pervena, A ^a   Klouvas, G ^a   Galani, E ^a   Falagas, M E ^b   Tsakalos, G ^a   Visvikis, A ^a   Nikolakopoulou, A ^a   Acholos, V ^a   Karapanagiotidis, G ^a   Batziou, E ^a   Skarlos, D V ^a  

^a METROPOLITAN HOSPITAL   (Greece)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c Metropolitan Hospital   (Greece)

Author keywords

Antiangiogenic factors; Bevacizumab; Bisphosphonates; Osteonecrosis of the jaw

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; IBANDRONIC ACID; SORAFENIB; SUNITINIB; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE METASTASIS; BREAST CANCER; COLON CANCER; COLORECTAL CANCER; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS;

EID: 59749100961     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000201931     Document Type: Article

References (7)

1. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME: Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002;32:94-124.
2. Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117.
3. Durie BG, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102.
4. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
5. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A: Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-971.
6. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061.
7. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, Grilli C, Virzì V, Gasparro S, Rocci L, Tonini G: Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005;25:144-151.